uploads/2019/02/fish-oil-1915424_1280-1.jpg

What Wall Street Recommends for Amarin and Novavax

By

Updated

Share price movements

On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price, 746% higher than its 52-week low of $2.35, and 15% below its 52-week high of $23.33. The stock picked up momentum on rumors of a probable acquisition offer from Novartis (NVS), as reported by StreetInsider.com. Its market capitalization was $6.30 billion.

Based on its closing price on February 22, the company reported returns of 14.5% in the last week, 12.2% in the last month, 14.7% in the last quarter, 599.7% in the last half-year, 435.6% in the last year, and 46.00% year-to-date.

Novavax (NVAX) closed at $1.92, 1.1% higher than its previous closing price, 67.0% higher than its 52-week low of $1.15, and 30.2% below its 52-week high of $2.75. Its market capitalization was $759.26 million.

Based on its closing price on February 22, the company reported returns of -12.7% in the last week, -6.8% in the last month, 11.6% in the last quarter, 46.6% in the last half-year, -19.0% in the last year, and 4.4% year-to-date.

Article continues below advertisement

Analysts’ recommendations and target price

The 12-month consensus recommendation for Amarin and Novavax is “strong buy” and “buy,” respectively.

Of the four analysts covering Amarin, two recommend a “strong buy” and two recommend a “buy.” The 12-month target price is $34.00, 71.1% higher than its last closing price on February 21. The highest target price estimate for the company is $51, and the lowest is $20.

Of the nine analysts covering Novavax, three recommend a “strong buy,” four recommend a “buy,” and two recommend a “hold.” The 12-month target price is $4.38, 128.1% higher than its last closing price on February 22. The highest target price estimate for the company is $10, and the lowest is $1.5.

Next in this series, we’ll look at the revenue growth trajectory for Amarin and Novavax in greater detail. 

 

Advertisement

More From Market Realist